Small molecule sales at risk due to patent loss U.S. 2028

Small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028 (in billion U.S. dollars)

Projected small molecule sales at risk due to patent expiry in the U.S. 2019-2028

Last update:

Nov 25, 2024

Author:

��ƽ�� Research Department

Region:

United States

Survey time period:

From 01/01/2019 to 31/12/2026

This statistic depicts small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028. According to the data, in 2026, U.S. dollars are expected to be at risk due to the loss of exclusivity. Sales losses due to patent expiration will become more significant for biologic drugs than for small-molecule drugs.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028 (in billion U.S. dollars)

Get in touch with us for additional information

��ƽ��